Relay Therapeutics, Inc. RLAY EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Relay Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s EBITDA margin?
- Relay Therapeutics, Inc. (RLAY) reported EBITDA margin of -2,749.9% in Q1 2026.
- How has Relay Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Relay Therapeutics, Inc.'s EBITDA margin increased by 41.6% year-over-year, from -4,710.2% to -2,749.9%.
- What is the long-term trend for Relay Therapeutics, Inc.'s EBITDA margin?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s EBITDA margin has grown at a -36.4% compound annual growth rate (CAGR), from -11,910.6% to -1,948.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.